NCT07422805Active, not recruitingPhase 1/2
Circulating Tumor DNA in Melanoma Patients
Significance of Detection and Quantification of Circulating Tumor DNA in the Treatment of Melanoma Patients
Source: ClinicalTrials.gov · Last updated 27 May 2026
Brief summary (registry, in English)
The aim of this prospective clinical study is to determine whether the presence and quantity of circulating tumor DNA (ctDNA) can serve as a predictive factor for recurrence or progression of melanoma. The study evaluates the association between ctDNA detection and quantification and relevant clinical and histopathological prognostic parameters. The goal is to assess whether ctDNA may be useful as a biomarker for monitoring disease course and predicting outcomes in melanoma patients.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 176 (actual)
- First submitted
- 5 Feb 2026
- Start date
- 1 Nov 2021
- Primary completion date
- 30 Nov 2023
- Lead sponsor
- Institute of Oncology Ljubljana
- Diseases
- Melanoma
- NCT number
- NCT07422805
What you commit to
- Study type: Interventional · Phase 1/2
- Participants enrolled: 176
- From 1 Nov 2021 to the primary completion date, 30 Nov 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Any condition that, in the investigator's opinion, makes the patient unsuitable for participation.
Other
- Patients unable to provide blood samples.
- Patients with missing clinical or histopathological data required for analysis.
Who the study is looking for
- Adult patients (≥ 18 years).
- Patients with histologically confirmed melanoma.
- Patients undergoing treatment and/or follow-up at the Institute of Oncology Ljubljana.
- Availability of clinical follow-up data to assess recurrence or progression.
- Ability to provide blood samples for ctDNA analysis.
- Signed informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institute of Oncology Ljubljana Coordinator of this site? Confirm its status | Ljubljana | Slovenia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.